Get the Stockscreener App
15.13
3.12%
-0.43
Arcus Biosciences Inc stock is traded at $15.13, with a volume of 216.53K.
It is down -3.12% in the last 24 hours and down -9.47% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$15.56
Open:
$15.41
24h Volume:
216.53K
Relative Volume:
0.34
Market Cap:
$1.40B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-3.8207
EPS:
-3.96
Net Cash Flow:
$-267.00M
1W Performance:
-8.14%
1M Performance:
-9.47%
6M Performance:
-3.99%
1Y Performance:
-7.92%
1-Day Range:
$15.03
$15.50
1-Week Range:
$15.00
$16.71
52-Week Range:
$12.95
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer - StockTitan
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
(RCUS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
This Arcus Biosciences Insider Reduced Their Stake By 27% - Simply Wall St
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - MSN
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - StockTitan
Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Arcus Biosciences: Advancing On Several Fronts (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3%Should You Sell? - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $29.00 at Barclays - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials - Investing.com India
Arcus Begins Differentiating Its HIF-2a inhibitor Versus Merck’s Welireg - Scrip
Arcus Biosciences Announces New Employment Inducement Grants - StockTitan
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - Marketscreener.com
Citi raises Arcus Biosciences target to $46, maintains buy By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) PT Raised to $46 at Citi - StreetInsider.com
Neutral stance on Arcus Biosciences maintained by BofA - Investing.com Canada
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS) - StreetInsider.com
Arcus Biosciences (NYSE:RCUS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (NYSE: RCUS) Could Slash -153.89% Soon - Stocks Register
Arcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage Trial - MarketWatch
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - StockTitan
(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily
Arcus Begins Differentiating Its HIF-2a Inhibitor Versus Merck’s Welireg - Citeline
Arcus started at neutral by H.C. Wainwright, upcoming data cited - MSN
Research Analysts Issue Forecasts for RCUS Q3 Earnings - MarketBeat
Exchange Traded Concepts LLC Has $152,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
HC Wainwright Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - Defense World
PD-1 Non-Small Cell Lung Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Summit Therapeutics, Arcus Biosciences,GSK, Pfizer - The Globe and Mail
HC Wainwright & Co. Initiates Coverage of Arcus Biosciences (RCUS) with Neutral Recommendation - MSN
Arcus started at neutral by H.C. Wainwright, upcoming data cited (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Shares Gap DownTime to Sell? - MarketBeat
Neutral rating set for Arcus Biosciences shares ahead of data release - Investing.com UK
Unveiling 5 Analyst Insights On Arcus Biosciences - Benzinga
Where Arcus Biosciences Stands With Analysts - Benzinga
Arcus Biosciences (NYSE:RCUS) Receives New Coverage from Analysts at HC Wainwright - MarketBeat
State Street Corp's Strategic Adjustment in Arcus Biosciences Ho - GuruFocus.com
December 20th Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
SG Americas Securities LLC Decreases Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Inc (RCUS)’s results reveal risk - US Post News
PD-1 and PDL-1 Inhibitors Market -2032 Demanding Key Players like GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc. – Cauverynews - Cauverynews
Objective long/short (RCUS) Report - Stock Traders Daily
Squarepoint Ops LLC Purchases New Shares in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) PT at $34.88 - MarketBeat
Commit To Buy Arcus Biosciences At $15, Earn 30.4% Annualized Using Options - Nasdaq
The RCUS Stock Puzzle: Unraveling Arcus Biosciences Inc’s Fluctuating Performance - The InvestChronicle
Arcus Biosciences (NYSE:RCUS) Shares Down 5.1%Should You Sell? - MarketBeat
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):